103 related articles for article (PubMed ID: 38855599)
1. Combination therapies targeting different aspects of tumor biology for patients with advanced urothelial carcinoma.
Miyake M
Transl Androl Urol; 2024 May; 13(5):902-908. PubMed ID: 38855599
[No Abstract] [Full Text] [Related]
2. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
Ng KYY; Wong LWJ; Ang AJS; Lee AWX; Tay DSH; Tan JJE; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2023 Jun; 19(3):312-319. PubMed ID: 35950298
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study.
Iinuma K; Yamada T; Kameyama K; Taniguchi T; Kawada K; Ishida T; Nagai S; Enomoto T; Ueda S; Takagi K; Kawase M; Takeuchi S; Kawase K; Kato D; Takai M; Nakane K; Koie T
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765903
[TBL] [Abstract][Full Text] [Related]
5. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
Yang Y; Psutka SP; Parikh AB; Li M; Collier K; Miah A; Mori SV; Hinkley M; Tykodi SS; Hall E; Thompson JA; Yin M
Cancer Med; 2022 Aug; 11(16):3106-3114. PubMed ID: 35304832
[TBL] [Abstract][Full Text] [Related]
6. Role of Immune Checkpoint Inhibitor Therapy in Advanced
Wiest N; Majeed U; Seegobin K; Zhao Y; Lou Y; Manochakian R
Front Oncol; 2021; 11():751209. PubMed ID: 34868953
[TBL] [Abstract][Full Text] [Related]
7. Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma.
Sano T; Saito R; Aizawa R; Watanabe T; Murakami K; Kita Y; Masui K; Goto T; Mizowaki T; Kobayashi T
Int J Clin Oncol; 2023 Dec; 28(12):1573-1584. PubMed ID: 37874429
[TBL] [Abstract][Full Text] [Related]
8. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
9. The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers.
Starzer AM; Wolff L; Popov P; Kiesewetter B; Preusser M; Berghoff AS
Cancer Treat Rev; 2024 Apr; 125():102718. PubMed ID: 38521009
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor.
Sawada T; Narukawa M
Cancer Control; 2024; 31():10732748241244586. PubMed ID: 38581169
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study.
Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Ikeda T; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T
Target Oncol; 2023 Mar; 18(2):209-220. PubMed ID: 36941516
[TBL] [Abstract][Full Text] [Related]
12. Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma.
Stühler V; Rausch S; Maas JM; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Sep; 21(9):1215-1226. PubMed ID: 33576709
[TBL] [Abstract][Full Text] [Related]
13. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.
Kawashima A; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Nonomura N
Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38850448
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma.
Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T
Target Oncol; 2023 Jan; 18(1):159-168. PubMed ID: 36571708
[TBL] [Abstract][Full Text] [Related]
15. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
16. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
[No Abstract] [Full Text] [Related]
17. Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.
Hu Y; Pan T; Cai X; He QS; Zheng YB; Huang MS; Jiang ZB; Chen JW; Wu C
J Gastrointest Oncol; 2023 Aug; 14(4):1837-1848. PubMed ID: 37720446
[TBL] [Abstract][Full Text] [Related]
18. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
Ishihara H; Omae K; Nemoto Y; Ishiyama R; Tachibana H; Nishimura K; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
Int J Clin Oncol; 2024 Apr; 29(4):473-480. PubMed ID: 38345708
[TBL] [Abstract][Full Text] [Related]
19. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.
Zeng H; Xu Q; Wang J; Xu X; Luo J; Zhang L; Luo C; Ying J; Li J
Front Immunol; 2023; 14():1073133. PubMed ID: 36756114
[TBL] [Abstract][Full Text] [Related]
20. Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Chan DW; Choi HC; Lee VH
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
